Home

news007

in vivo Pharmacodynamic Assay

Trevigen offers a validated assay with higher sensitivity and pre-coated antibody plates to measure the effectiveness of PARP inhibitors in cell and tissue lysates for anticancer drug screening.

In cancer drug development, a current molecular target of high interest is poly (ADP-ribose) polymerase (PARP), which is involved in DNA repair and the survival or death of cancer cells. Measuring the effectiveness of PARP inhibitors in cell and tissue lysates has been difficult and time consuming due to a lack of refined immunological reagents in an optimized and quantitative assay.

Trevigen’s HT PARP in vivo Pharmacodynamic Assay II is a high throughput, Chemiluminescent, PAR ELISA assay kit that has been validated on human peripheral blood lymphocytes and also shown to work with normal and tumor tissue.  The assay features pre-coated capture antibody plates, broad linear dynamic range to 1,000 pg/ml, high signal to noise ratio, and detection sensitivity of 2 pg/ml of PAR. The amount of PAR present correlates directly with the activity of the PARP enzyme in cell lysates. The assay can be used to quantify PAR in peripheral blood mononuclear cells, tissues, and cultured cells.

Source: Trevigen, Inc.

News & Events

  • FDA Says Additional Pixuvri Trial Needed, CTI Opens Drug to Expanded Access Cell Therapeutics... Read more>>
  • Key Protein Aids In DNA Repair Scientists have shown in multiple contexts that DNA damage ov... Read more>>
  • GSK Receives EMEA Approval for Duodart LONDON (AP) - Pharmaceutical company GlaxoSmithKline... Read more>>
  • Novozymes Partnering With ProMetic Life Sciences Inc.Drug Discovery & Development - April 0... Read more>>
  • FDA Requests More Information on Certriad LONDON (AP) - AstraZeneca PLC and Abbott Laborator... Read more>>
  • T Cell Proliferation Assays ProImmune Ltd, a leader in epitope discovery, immunogenicity, an... Read more>>
  • Mapping Technique Speeds Finding Specific Genes A Purdue University scientist was part of a... Read more>>
  • FDA Approves Mylan’s Drug Applications Mylan Inc. Monday announced that its subsidiary Mylan Ph... Read more>>
  • Statins May Slow Progression Of Multiple Sclerosis, New Study Finds A UCSF-led study exa... Read more>>
  • Food and Drug Administration NOTICES Meetings:   Internationa... Read more>>
  • U.S. Food & Drug Administration (FDA) New and Generic Drug Approvals Calan (verapamil h... Read more>>
  • Pending Litigation to Delay Launch of Generic Asacol Boehringer Ingelheim’s Roxane Laboratori... Read more>>